Winlevi Set to Revolutionize Acne Treatment in Europe

Glenmark Pharmaceuticals Ltd, in collaboration with Ireland's Cosmo Pharmaceuticals N.V., has secured marketing authorisation from the European Commission for Winlevi, a novel acne treatment cream. This marks a significant milestone for Glenmark's expansion in dermatology within Europe, empowering adolescents and adults with a first-in-class topical solution.

Glenmark Pharmaceuticals Ltd, together with Ireland's Cosmo Pharmaceuticals N.V., has announced that the European Commission has granted marketing authorisation for Winlevi, an innovative acne treatment, across 15 European countries.

The European Medicines Agency's Committee for Medicinal Products for Human Use's positive opinion on August 25, 2025, set the stage for this landmark approval. This moment represents Glenmark's prominent stride towards becoming a global research-led pharmaceutical powerhouse, according to Christoph Stoller, President & Business Head for Europe and Emerging Markets.

The approval enables Winlevi to treat acne vulgaris in individuals aged 12 to 18 in these nations, available for facial application in adolescents. Glenmark plans to launch Winlevi commercially in countries including France, Spain, and Sweden, reflecting the successful collaboration with Cosmo Pharmaceuticals and their shared goal of enhancing dermatologic care.

(With inputs from agencies.)